A bifunctional sdAb, targeting EGFR and TRAIL, inhibits the growth of different tumor cell types that were not responsive to either EGFR-antagonist or death receptor-agonist monotherapies is a clear step forward of the clinical application of sdAb modules (23). The gene discussed is EGFR; the disease is neoplasm.